Roche expands partnership with Bio-Techne to offer drug discovery researchers new chromogenic detection options for mRNA ISH tissue analysis
New Roche detection kits, combined with Bio-Techne's ACD RNAscope® reagent kits, increase singleplex and multiplex testing capabilities on automated platform
INDIANAPOLIS, May 6, 2019 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has expanded its partnership with Bio-Techne by offering drug discovery researchers in the U.S. new chromogenic detection kits for automated in situ hybridization (ISH) tissue analysis.
The new Roche kits include the DISCOVERY mRNA Purple HRP detection kit (RUO) and the DISCOVERY mRNA Teal HRP detection kit (RUO). The purple and teal detection kits feature more translucent dyes that are ideal for co-localization studies for mRNA ISH as well as the ability to perform immunohistochemistry (IHC) and ISH for protein-RNA co-detection on the same slide. Both kits are designed to be used on the Roche DISCOVERY ULTRA staining platform alongside the recently released Advanced Cell Diagnostics (ACD) RNAscope VS Universal HRP Reagent Kit, which offers improved signal-to-noise ratio and robustness.
In addition, Roche's mRNA Duplex AMP kit (RUO) now has an expanded application that enables the new mRNA Teal HRP detection kit to be used with Roche's existing mRNA RED detection kit (RUO) for dual mRNA ISH detection. The teal/red combination provides a distinct visual contrast and the translucency of the teal dye allows for studying co-expression of mRNA ISH targets, where the resulting teal and red dyes overlap to produce an indigo color. This new application is intended to be used with the recently released RNAscope VS Duplex Reagent Kit, which delivers simultaneous in situ detection of two mRNA species.
"Expanding our partnership with Bio-Techne enables Roche to offer scientists a broader suite of tools to expand their tissue research capabilities," said Holly Egan, vice president of marketing for tissue diagnostics at Roche Diagnostics Corporation. "Giving researchers the opportunity to automate these assays on a Roche platform helps them save time and generate data faster to accelerate drug discovery research."
The new detection kits and dual mRNA ISH application enable researchers to increase their multiplexing possibilities, optimize staining conditions for challenging antibodies and probes, easily run complex assays, conserve tissue samples and save time.
"We're pleased to partner with Roche to provide researchers access to a fully automated, optimized solution for the performance of RNAscope, our highly sensitive and specific RNA ISH technology for the detection of any RNA in any species," said Kim Kelderman, president of Diagnostics and Genomics at Bio-Techne Corporation. "The expanded chromogenic detection options on the Roche platform provide our customers with exceptional visualization and flexibility for RNAscope staining and ISH-IHC co-staining."
Widely used in cancer research, ISH and IHC tissue-staining methods provide information that helps researchers better understand mechanisms of disease and accelerate drug development. Automating ISH and IHC on the DISCOVERY ULTRA platform enables scientists to generate standardized, reproducible results and eliminate over 90 percent of manual processes so they can spend more time focusing on their research.
The mRNA ISH detection kits from Roche are intended for research use only on the DISCOVERY ULTRA platform with the ACD RNAscope reagent kits from Bio-Techne.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. Bio-Techne's portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. Bio-Techne's genomic tools include advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx®Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $643 million in net sales in fiscal 2018 and has over 2,100 employees worldwide.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognized as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com or diagnostics.roche.com.
All trademarks used or mentioned in this release are protected by law.
The DISCOVERY mRNA Purple HRP detection kit (RUO), the DISCOVERY mRNA Teal HRP detection kit (RUO), the mRNA RED detection kit (RUO), the mRNA Duplex AMP kit (RUO), and the DISCOVERY ULTRA system are for research use only. Not for use in diagnostic procedures.
For more information, please contact:
Roche Diagnostics Corporation
Indianapolis, Indiana USA
1 317 371 0035
View original content to download multimedia:http://www.prnewswire.com/news-releases/roche-expands-partnership-with-bio-techne-to-offer-drug-discovery-researchers-new-chromogenic-detection-options-for-mrna-ish-tissue-analysis-300843394.html
SOURCE Roche Diagnostics
Company Codes: NASDAQ-NMS:TECH, OTC-PINK:RHHBY, Swiss:RO, Swiss:ROG, OTC-QX:RHHBY